利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

18 条记录 (耗时 0.03 秒)

    TREATMENT OR PREVENTION OF INFLAMMATION BY TARGETING CYCLIN D1
    1.
    发明申请
    TREATMENT OR PREVENTION OF INFLAMMATION BY TARGETING CYCLIN D1 审中-公开
    通过定期循环D1治疗或预防炎症

    公开(公告)号：US20100285002A1

    公开(公告)日：2010-11-11

    申请号：US12811229

    申请日：2008-12-30

    申请人： Dan Peer ,  Motomu Shimaoka

    发明人： Dan Peer ,  Motomu Shimaoka

    IPC分类号： A61K39/395 ,  A61K31/7088 ,  A61P37/00 ,  A61P29/00 ,  A61P25/28 ,  A61P19/02

    CPC分类号： C12N15/113 ,  C12N2310/14

    摘要： In one aspect, the invention relates to the treatment and/or prevention of inflammation by inhibition of cyclin D1. In one embodiment, Th1-mediated inflammation is selectively inhibited or reduced by a method comprising administering an agent that inhibits cyclin D1. In another embodiment, an autoimmune disease or a disorder characterized by or involving a Th1 inflammatory response is treated or prevented in a subject by a method comprising administering to the subject an agent that inhibits cyclin D1.

    摘要翻译： 一方面，本发明涉及通过抑制细胞周期蛋白D1治疗和/或预防炎症。 在一个实施方案中，通过包括施用抑制细胞周期蛋白D1的试剂的方法选择性地抑制或减少Th1介导的炎症。 在另一个实施方案中，通过包括向受试者施用抑制细胞周期蛋白D1的药物的方法，在受试者中治疗或预防特征为或涉及Th1炎症反应的自身免疫疾病或病症。

    TARGETED DELIVERY TO LEUKOCYTES USING PROTEIN CARRIERS
    2.
    发明申请
    TARGETED DELIVERY TO LEUKOCYTES USING PROTEIN CARRIERS 审中-公开
    使用蛋白质载体的目标交付给LEUKOCYTES

    公开(公告)号：US20130129752A1

    公开(公告)日：2013-05-23

    申请号：US12298361

    申请日：2007-04-25

    申请人： Dan Peer ,  Motomu Shimaoka ,  Judy Lieberman

    发明人： Dan Peer ,  Motomu Shimaoka ,  Judy Lieberman

    IPC分类号： A61K39/395 ,  C12N5/06 ,  A61K35/12 ,  C07K16/18

    CPC分类号： C12N15/87 ,  A61K2039/55555 ,  C12N15/111 ,  C12N15/1138 ,  C12N2310/14 ,  C12N2320/32

    摘要： Disclosed herein are is a leukocyte-selective delivery agent comprising, a targeting moiety that selectively binds LFA-I, a protein carrier moiety covalently linked to the targeting moiety, and a therapeutic agent associated with the carrier moiety. The delivery agent may be further selective for activated leukocytes, wherein the targeting moiety selectively binds LFA-I in its activated conformation. The targeting moiety comprises an antibody or functional fragment thereof, such as an scFV. Examples of antibodies or fragments thereof which selectively bind LFA-I activated conformation bind to the locked open I domain of LFA-I, or binds to the leg domain of the β2 subunit of LFA-I ((ILP2)—The antibody or functional fragment thereof may alternatively bind non-selectively to both low affinity and high affinity LFA-I. Examples of a non-protein carrier are a basic polypeptide such as protamine or a functional fragment thereof. One such fragment is RSQSRSRYYRQRQRSRRRRRRS. The therapeutic agent may comprise one or more of a nucleic acid, a small molecule, a polypeptide, and an antibody or functional fragment thereof. An example of a nucleic acid delivery agent comprises an RNA interference molecule. Examples of RNA interference molecules are siRNA, dsRNA, StRNA, shRNA, miRNA, and combinations thereof. Specific siRNAs are provided. Other examples of a nucleic acid delivery agent are a small RNA, an antagomir, an LNA, and an antisense oligonucleotide. Methods for leukocyte-selective delivery, or activated leukocyte-selective delivery in vivo, in vitro and ex vivo are also provided.

    摘要翻译： 本文公开的是白细胞选择性递送剂，其包含选择性结合LFA-1的靶向部分，与靶向部分共价连接的蛋白质载体部分和与载体部分相关联的治疗剂。 递送剂可以对活化的白细胞进一步选择性，其中靶向部分选择性地结合其活化构象中的LFA-1。 靶向部分包含抗体或其功能片段，例如scFV。 选择性结合LFA-1激活的构象的抗体或其片段的实例与LFA-1的锁定的开放I结构域结合，或与LFA-1（（ILP2））的β2亚基的腿结构域结合 - 抗体或功能片段 非蛋白质载体的实例可以是碱性多肽，例如鱼精蛋白或其功能片段，一个这样的片段是RSQSRSRYYRQRQRSRRRRRRS，治疗剂可以包含一种 核酸分子的实例包括RNA干扰分子，RNA干扰分子的实例是siRNA，dsRNA，StRNA，shRNA， miRNA及其组合提供特异性siRNA，核酸递送剂的其它实例是小RNA，antagomir，LNA和反义寡核苷酸。白细胞选择方法 还提供体外和离体的活性递送或活化的白细胞选择性递送。

    METHODS OF DELIVERY OF AGENTS TO LEUKOCYTES AND ENDOTHELIAL CELLS
    4.
    发明申请
    METHODS OF DELIVERY OF AGENTS TO LEUKOCYTES AND ENDOTHELIAL CELLS 审中-公开
    向白细胞介素和内皮细胞递送药物的方法

    公开(公告)号：US20110177155A1

    公开(公告)日：2011-07-21

    申请号：US12674504

    申请日：2008-08-20

    申请人： Dan Peer ,  Motomu Shimaoka

    发明人： Dan Peer ,  Motomu Shimaoka

    IPC分类号： A61K9/127 ,  C12N5/00 ,  C12N5/071

    CPC分类号： A61K31/337 ,  A61K31/7088 ,  A61K45/06 ,  A61K47/6913 ,  A61K47/6929 ,  B82Y5/00 ,  A61K2300/00

    摘要： The present invention generally relates to methods and compositions for the simultaneous delivery of at least one insoluble agent and at least one soluble agent to a cell. In particular the present invention relates to methods and compositions for the dual delivery of an insoluble agent and a soluble agent to a particular target cell, for example, a leukocyte or endothelial cell. In particular, methods and compositions for simultaneous delivery of a hydrophilic (i.e. soluble) agent and/or a hydrophobic (i.e. insoluble) agent to a leukocyte cell or endothelia cell are disclosed.

    摘要翻译： 本发明一般涉及用于将至少一种不溶性试剂和至少一种可溶性试剂同时递送至细胞的方法和组合物。 特别地，本发明涉及用于将不溶性试剂和可溶性试剂双重递送至特定靶细胞例如白细胞或内皮细胞的方法和组合物。 特别地，公开了将亲水（即可溶性）试剂和/或疏水性（即不溶性）试剂同时递送至白细胞或内皮细胞的方法和组合物。

    TARGETED DELIVERY TO LEUKOCYTES USING NON-PROTEIN CARRIERS
    5.
    发明申请
    TARGETED DELIVERY TO LEUKOCYTES USING NON-PROTEIN CARRIERS 审中-公开
    使用非蛋白载体的目标交付给白蛋白

    公开(公告)号：US20100008937A1

    公开(公告)日：2010-01-14

    申请号：US12298367

    申请日：2007-04-25

    申请人： Dan Peer ,  Motomu Shimaoka

    发明人： Dan Peer ,  Motomu Shimaoka

    IPC分类号： A61K47/48 ,  C07H21/02 ,  C07K2/00 ,  A61K9/127 ,  A61K38/02 ,  A61K39/395 ,  C12N5/00 ,  A61K35/00

    CPC分类号： C12N15/87 ,  A61K2039/55555 ,  C12N15/111 ,  C12N15/1138 ,  C12N2310/14 ,  C12N2320/32

    摘要： Disclosed are delivery agents for selective delivery to leukocytes. The leukocyte-selective delivery agents comprise a targeting moiety that selectively binds LFA-I, a non-protein carrier moiety covalently linked to the targeting moiety and a therapeutic agent associated with the carrier moiety. The non-protein carrier moiety comprises a liposome, a micelle, or a polymeric nanoparticle comprised of PLA or PLGA. The delivery agent may be further selective for activated leukocytes by using a targeting moiety that selectively binds LFA-I in its activated conformation. The targeting moiety may comprise an antibody or functional fragment thereof such as an scFV. Appropriate therapeutic agents include a nucleic acid, a small molecule, a polypeptide, and an antibody or functional fragment thereof. Additional examples of therapeutic agents are a small RNA, an antagomir, an LNA, or an antisense oligonucleotide. One such therapeutic agent is an RNA interference molecule such as siRNA, dsRNA, stRNA, shRNA, miRNA. Specific delivery agents are provided. Methods for in vivo, in vitro and ex vivo leukocyte-selective delivery using the delivery agents are also disclosed.

    摘要翻译： 公开了用于选择性递送至白细胞的递送剂。 白细胞选择性递送剂包含选择性结合LFA-1的靶向部分，LFA-1是与靶向部分共价连接的非蛋白质载体部分和与载体部分相关联的治疗剂。 非蛋白质载体部分包含脂质体，胶束或由PLA或PLGA组成的聚合物纳米颗粒。 通过使用选择性结合其活化构象中的LFA-1的靶向部分，递送剂可以进一步选择性地活化白细胞。 靶向部分可以包含抗体或其功能片段，例如scFV。 合适的治疗剂包括核酸，小分子，多肽，抗体或其功能片段。 治疗剂的其它实例是小RNA，antagomir，LNA或反义寡核苷酸。 一种这样的治疗剂是RNA干扰分子，例如siRNA，dsRNA，stRNA，shRNA，miRNA。 提供特定的递送剂。 还公开了使用递送剂的体内，体外和离体白细胞选择性递送的方法。

    CELL-TARGETING NANOPARTICLES COMPRISING POLYNUCLEOTIDE AGENTS AND USES THEREOF
    7.
    发明申请
    CELL-TARGETING NANOPARTICLES COMPRISING POLYNUCLEOTIDE AGENTS AND USES THEREOF 有权
    包含多核苷酸代谢物的细胞靶向纳米颗粒及其用途

    公开(公告)号：US20120129916A1

    公开(公告)日：2012-05-24

    申请号：US13388161

    申请日：2010-07-29

    申请人： Dan Peer

    发明人： Dan Peer

    IPC分类号： A61K31/7088 ,  C07H21/02 ,  C07H21/00 ,  C07K1/00 ,  C07K1/107 ,  A61P35/00 ,  C12N5/071 ,  C07H21/04 ,  B82Y40/00 ,  B82Y5/00

    CPC分类号： A61K9/5161 ,  A61K9/1272 ,  A61K9/5123 ,  A61K47/6849 ,  A61K47/6935 ,  A61K47/6939 ,  B82Y5/00 ,  C12N15/113 ,  C12N15/87 ,  C12N15/88 ,  C12N2310/14 ,  C12N2310/141 ,  Y10T428/2982 ,  Y10T428/2991

    摘要： A method of generating a particle is disclosed, the particle being for delivery of a polynucleotide to a target cell. The method comprises (a) contacting the polynucleotide with a composition comprising cationic molecules, wherein the cationic molecules condense the polynucleotide by electrostatic interactions to generate a complex, wherein the cationic molecules are not comprised in a liposome; and (b) covalently binding the complex to a targeting moiety at a pH equal to or below about 4.5, thereby generating the particle for delivery of the polynucleotide agent to the target cell. Use of the particles and compositions comprising same are also disclosed.

    摘要翻译： 公开了产生颗粒的方法，所述颗粒用于将多核苷酸递送至靶细胞。 该方法包括：（a）使多核苷酸与包含阳离子分子的组合物接触，其中阳离子分子通过静电相互作用浓缩多核苷酸以产生复合物，其中阳离子分子不包含在脂质体中; 和（b）在等于或低于约4.5的pH下将复合体与靶向部分共价结合，由此产生用于将多核苷酸试剂递送至靶细胞的颗粒。 还公开了包含它们的颗粒和组合物的用途。